Last reviewed · How we verify
CD7 CART
At a glance
| Generic name | CD7 CART |
|---|---|
| Sponsor | Qi deng |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma (PHASE1)
- SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (PHASE1, PHASE2)
- uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (PHASE1)
- Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL (PHASE2)
- CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia (NA)
- Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia (NA)
- Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL (NA)
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD7 CART CI brief — competitive landscape report
- CD7 CART updates RSS · CI watch RSS
- Qi deng portfolio CI